Elotuzumab
CAS No. 915296-00-3
Elotuzumab( —— )
Catalog No. M34757 CAS No. 915296-00-3
Elotuzumab(HuLuc 63) is a monoclonal antibody that targets the SLAMF7 receptor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 360 | In Stock |
|
| 5MG | 655 | In Stock |
|
| 10MG | 924 | In Stock |
|
| 25MG | 1359 | In Stock |
|
| 50MG | 1795 | In Stock |
|
| 100MG | 2446 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameElotuzumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionElotuzumab(HuLuc 63) is a monoclonal antibody that targets the SLAMF7 receptor.
-
DescriptionElotuzumab is a monoclonal antibody directed against the SLAMF7 receptor. Elotuzumab has no significant antimyeloma activity when given as a single agent with relapsed or refractory multiple myeloma (RRMM). Elotuzumab results in improved response and outcome when combined with other antimyeloma agents.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number915296-00-3
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Magen H, et al. Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment. Ther Adv Hematol. 2016;7(4):187-195.
molnova catalog
related products
-
SL-327
SL327 is a selective inhibitor for MEK1/2 with IC50 of 0.18 μM/0.22 μM; able to transport through the blood-brain barrier.
-
Betahistine
Betahistine is a histamine analog and H1 receptor agonist that serves as a vasodilator.
-
Compound 35
Compounds 35 are superior inhibitors of Ebola (Mayinga) and Marburg (Angola) infectious viruses.Compounds 35 are superior inhibitors of Ebola (Mayinga) and Marburg (Angola) infectious viruses. Compounds 35 have shown good metabolic stability in plasma and liver microsomes (rat and human), and 32 did not inhibit CYP3A4 nor CYP2C9.
Cart
sales@molnova.com